and has been licensed since 1997 for the treatment of several types of non-Hodgkin lymphoma, including follicular lymphoma, previously untreated diffuse large B-cell lymphoma and chronic ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

The two main types are B lymphocytes (B cells ... courses and respond differently to treatments: Diffuse large B cell lymphoma (DLBCL) is cancer involving B cells. Under the microscope, the ...

Kim (58, female) was a recurrent diffuse giant B-cell lymphoma and did not respond to existing chemotherapy, but received ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

The Burkitt lymphoma market is expected to experience significant growth across the seven major markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Sp ...